

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#5

IN RE APPLICATION OF: WAINER, Irving, et al.

GROUP ART UNIT:

SERIAL NUMBER: 10/009,344

EXAMINER:

FILED: 08 APRIL 2002

FOR: CHROMATOGRAPHIC DETERMINATION OF P-GLYCOPROTEIN REACTIVE LIGANDS

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicant(s) wish(es) to disclose the following information.

REFERENCES

- Applicant(s) wish(es) to make of record the documents listed on the attached Form PTO-1449. Copies of Documents AA, AL, AM, AN, and AO are of record as these were cited in the Search Report issued by the ISA/US in the corresponding International (PCT) Application. Copies of Documents AJ and AK are attached.

RELATED CASES

- Attached is a list of Applicant's(s') pending applications and issued patents which may be related to the present application. Copies of the documents, where required, are attached along with Form PTO-1449.

CERTIFICATION

The undersigned certifies that

- each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign or international patent office in a counterpart foreign or international application for the first time (to the knowledge of the undersigned, having made reasonable inquiry) not more than three months prior to the filing of this statement.
- no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign or international patent office in a counterpart foreign or international application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement.

BASIS FOR CONSIDERATION

This Information Disclosure Statement is filed:

- without fee and within three months of the filing date of the application.
- without fee and within three months of the date of entry of the U.S. national stage.
- without fee and before the mailing date of a first Office Action on the merits (to the knowledge of the undersigned).
- without fee and with the appropriate certification above.
- without fee and with a new CPA application.
- without fee and with a Request for Continued Examination.
- with fee and before the mailing date of any of a Final Office Action, Notice of Allowance or an action that otherwise closes prosecution (to the knowledge of the undersigned).
- with fee, appropriate certification above, and before payment of the Issue Fee.

DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to Deposit Account No. 50-1442.

Respectfully submitted,

PIPER RUDNICK LLP


Steven B. Kelber

Attorney of Record

Registration No. 30,073

1200 Nineteenth Street, N.W.
Washington, DC 20036-2412
Telephone No. (202) 861-3900
Facsimile No. (202) 223-2085

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		DOCKET NO. 1908-006-27		SERIAL NO. 10/009,344	
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)				APPLICANT WAINER, Irving, et al.			
				FILING DATE 08 APRIL 2002		GROUP ART UNIT	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	4,837,306	06-06-89	LING, et al.			
	AB						
	AC						
	AD						
	AE						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION YES NO	
	AF						
	AG						
	AH						
	AI						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AJ	Wallsten, et al., "Entrapment of lipid vesicles and membrane protein-lipid vesicles in gel bead pores", Biochim. Biophys. Acta, 982:47-52 (1989).					
	AK	Yang, et al., "Steric Immobilization of Liposomes in Chromatographic Gel Beads and Incorporation of Integral Membrane Proteins into Their Lipid Bilayers", Anal. Biochem., 218:210-221 (1994).					
	AL	Zhang, et al., "Development of an Immobilized P-glycoprotein Stationary Phase for on-line Liquid Chromatographic Determination of Binding Affinities", Journal of Chromatography. B, Biomedical Sciences and Applications, 739(1):33-37 (2000).					
	AM	Gianni, et al., "Human Pharmacokinetic Characterization and In-vitro Study of the Interaction Between Doxorubicin and Paclitaxel in Patient with Breast Cancer", Journal of Clinical Oncology, 15(5):1906-1915 (1997).					
	AN	Sparreboom, et al., "Clinical Pharmacokinetics of Doxorubicin in Combination with GF 120918, a Potent Inhibitor of MDR1-P-glycoprotein", Anti-Cancer Drugs, 10(8):719-728 (1999).					
	AO	Kubota, et al., "Pirarubicin might partly circumvent the P-glycoprotein-mediated Drug Resistance of Human Breast Cancer Tissues", Anticancer Research, 18(2A):967-972 (1998).					
	AR						
EXAMINER					DATE CONSIDERED		
<p>*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>							